MedTrace Logo

Fall Prevention by Alfacalcidol and Training

NCT00483275 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 484

Last updated 2011-07-21

No results posted yet for this study

Summary

Objective of the study is to evaluate the effect of a multimodal therapy on the basis of current guidelines on fall prevention consisting of a 12-months intervention with Alfacalcidol and calcium, patient education and a mobility program in a group of patients 65 years of age or older with an impaired renal function in comparison to a group receiving usual care.

Conditions

  • Accidental Falls
  • Chronic Renal Insufficiency
  • Aged

Interventions

DRUG

Alfacalcidol

BEHAVIORAL

Balance, gait and strength training

BEHAVIORAL

Patient education

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Ruhr University of Bochum

    lead OTHER

Principal Investigators

  • Prof. Dr. med. Ludger Pientka, MD, MPH · Klinik für Altersmedizin und Frührehabilitation, Marienhospital Herne, Ruhr-Universität Bochum

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Completion
2009-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483275 on ClinicalTrials.gov